Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma (NCT01222286), a randomized phase 2 study. The primary outcome is Rate of Patients Achieving an Objective Response.

2. Clinical Question

The study compared two dose regimens rather than IPH2101 with a placebo or no-treatment group. Its primary question was about response activity during the study period, not about a direct comparison with another therapy or about long-term outcomes. The registry record describes a response as one meeting International Myeloma Working Group uniform response criteria, including minimal response derived from European Society for Blood and Marrow Transplantation criteria. A response had to be confirmed on consecutive assessments 4 weeks apart.

The posted primary outcome records zero participants achieving the outcome in the 0.2 mg/kg arm and zero in the 2 mg/kg arm. This is the observed result for the stated endpoint and analysis population. It does not, by itself, establish what would have happened under other treatment options, nor does it answer every question about safety, pharmacology, or other anti-tumor activity. Those were listed among the study’s secondary aims, but detailed secondary results are not reported in the registry record.

3. Trial Design

This was a randomized, open-label, parallel-group phase II study sponsored by Innate Pharma. The registry record lists enrollment of 30 participants with smoldering multiple myeloma. Participants were assigned to one of two IPH2101 dose regimens: 0.2 mg/kg or 2 mg/kg. The posted primary outcome counts include 16 participants in the lower-dose arm and 14 in the higher-dose arm.

Both regimens used intravenous administration every 4 weeks over 1 hour, for 6 or up to 12 cycles. The registry record does not explain how the planned number of cycles was determined for individual participants. Masking is listed as none, so the study was not described as blinded. The record identifies the allocation as randomized and the model as parallel, but further details about sequence generation, allocation concealment, or operational procedures are not reported in the registry record.

The study began in 2010-09, had primary completion in 2012-07, and is listed as completed. The primary outcome timeframe is described as from the start to the end of the study (14 months). The primary endpoint was the number or rate of participants meeting the confirmed-response definition at any time through study end. The registry also lists safety assessment, pharmacodynamics of IPH2101, and secondary anti-tumor activity as secondary outcomes.

Because both arms received IPH2101, the randomized contrast concerns dose regimen within this study. The design does not include a concurrent untreated or placebo group. The posted results therefore describe the outcomes in the enrolled study groups, while the registry record does not report further design details that would clarify the rationale for the dose comparison or the choice of enrollment size.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: All patients enrolled were screened in order to verify the inclusion/exclusion criteria. All patients enrolled (30 patients) were analyzed.

Overall Study

Analysis population for the primary outcome, as defined in the registry: The ITT population included all randomized subjects.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Rate of Patients Achieving an Objective Response, measured over from start to end of study (14 months).

The primary endpoint is the rate of participants achieving an objective response during the study. The registry defines response using International Myeloma Working Group uniform response criteria and includes minimal response as derived from European Society for Blood and Marrow Transplantation criteria. A qualifying response had to occur at any time until the end of the study and be confirmed on two consecutive assessments at 4 weeks interval.

A response endpoint gives a count of participants who met a prespecified clinical classification, rather than measuring a continuous change in a laboratory value or the time until an event. The registry record describes the analysis population as all randomized subjects. The posted outcome shows zero participants meeting the endpoint in the 0.2 mg/kg group and zero in the 2 mg/kg group.

Such an endpoint is used to describe whether participants achieved a defined response during the observation period. The confirmation requirement is intended to distinguish a response sustained across assessments from a finding at a single assessment. The endpoint does not summarize every aspect of disease course, treatment exposure, or safety. Nor does the response count alone describe how precisely the underlying response probability is estimated. That precision depends on the amount of information in the observed data and on the statistical method used to calculate uncertainty. Additional endpoint analysis details are not reported in the registry record.

7. Results Posted in the Registry

• IPH2101 2 mg/kg: 0.0% (0/14) versus 0.0% (0/16) on control; risk difference 0.0 percentage points (95% CI 0.0 to 0.0); unadjusted two-proportion z-test p = n/a.

8. Statistical Interpretation

9. Statistical Methods Explained

The primary endpoint is binary at the participant level: each randomized participant either met the confirmed-response definition or did not. The registry describes the outcome as a number and a rate. For this type of endpoint, the basic descriptive result is the number meeting the definition alongside the number assessed in each group. The posted counts are zero of 16 for IPH2101 0.2 mg/kg and zero of 14 for IPH2101 2 mg/kg. A risk difference expresses the difference between the two groups’ observed response proportions. The posted risk difference is 0.0.

The point estimate and its uncertainty answer different questions. The point estimate describes the observed contrast. An interval estimate is intended to show the range of values compatible with the data under a specified statistical method and assumptions. When no participants experience the event of interest, the observed risk is zero, but that does not establish that the underlying probability is zero. A confidence interval for a sparse binary outcome should reflect the finite information in the sample. The arm-level confidence limits are not reported in the registry record, and the comparison limits posted as 0.0 and 0.0 should not be interpreted as showing that the true difference is known with certainty.

The registry record identifies the comparison metric as a risk difference, but does not report the method used to calculate its uncertainty or a test statistic. No p-value is posted for the primary comparison. The analysis entries count is zero. It is therefore not possible to determine from the registry record whether the displayed comparison was intended as a formal inferential analysis, or to identify any particular test or interval procedure. No adjustment for baseline characteristics or other covariates is reported.

Randomization and masking describe different design features. Allocation is listed as randomized, while masking is listed as none. Random assignment can support comparisons by assigned group, while open-label conduct means that participants and study personnel were not described as blinded. The record does not describe random-sequence generation, allocation concealment, stratification, or methods for preventing knowledge of assignment from affecting assessments. These details are not reported in the registry record, so they should not be assumed.

The primary population is identified as the intention-to-treat population and is defined in the record as all randomized subjects. This indicates that the stated population is based on random assignment rather than only on participants who completed treatment. However, the registry does not give a participant flow account or explain how missing response assessments, withdrawals, or deviations were handled. It is not possible to establish from the record whether every randomized participant had complete endpoint data or how incomplete observations were classified.

The study lists safety assessment, pharmacodynamics, and secondary anti-tumor activity as secondary outcomes. The record gives a count of four outcome measures and lists three secondary outcome categories, but detailed outcome-level analysis plans are not reported. The number of analysis entries is zero, and no multiplicity strategy is reported. When a study evaluates several outcomes or comparisons, multiplicity can matter because repeated statistical testing can increase the chance of at least one apparently notable result. This is a general statistical consideration; the registry record does not state whether or how it was addressed.

The sample-size assumptions describe planning illustrations based on the observed effect, with a two-sided significance level of 0.05, equal allocation between arms, and a normal approximation. They specify that the effect to detect is a stated fraction of the observed effect. These are planning assumptions, not evidence about the trial’s original design rationale and not observed power. The trial’s own sample-size justification is not reported in the registry record. In particular, the record does not establish that the illustration assumptions were the assumptions used when enrollment was planned.

In general, power is a design property describing the chance of detecting a specified effect under stated assumptions. It is not a measure of how likely a conclusion from a completed trial is to be correct. Sample-size illustrations can show how requirements change under alternative assumed effects, but their meaning depends on the stated model, allocation, significance level, and target power. The record does not report the trial’s own target power or design calculations. Any illustration should therefore be read as a hypothetical planning exercise rather than as a description of what the study achieved.

All of these methods considerations point to a restrained reading. The posted data support a descriptive statement about the observed counts and the recorded risk difference. They do not supply enough analysis detail to reconstruct a formal test, an uncertainty interval suitable for interpretation, missing-data handling, or the original design rationale. Those elements are not reported in the registry record.

10. Confidence Intervals and Precision

Precision concerns how much uncertainty remains around an estimate. A confidence interval is a statistical range constructed using a specified method; it reflects the data and assumptions, rather than guaranteeing that the true value lies within the interval. For a binary endpoint, the amount of information depends on the number of participants and the number of observed events, along with the interval method.

Here, the posted primary outcome records zero responses among 16 participants in the 0.2 mg/kg group and zero among 14 participants in the 2 mg/kg group. The registry reports a risk difference of 0.0 and comparison limits of 0.0 and 0.0. It does not report arm-specific confidence intervals for the response rates, or identify the method behind the comparison limits. With no observed events, the point estimates alone should not be mistaken for precise estimates of the underlying response probabilities. Zero observed responses do not prove that the underlying probability is zero.

The posted comparison limits also should not be read as establishing that the true difference between regimens is exactly zero. The record does not explain how those limits were obtained, and the analysis entries count is zero. Without the interval method and more complete inferential reporting, the uncertainty around the dose contrast cannot be evaluated reliably from the registry record. The observed result is descriptively equal across groups; its precision is not established by the point estimate.

More generally, small samples and sparse outcomes often leave substantial uncertainty about event probabilities, even when observed counts match. This is a general statistical principle, not an additional result from this trial. No recalculated interval is reported in the record, and no interval should be inferred from the posted values alone.

11. Multiplicity, Missing Data and Analysis Populations

The registry record identifies the primary endpoint and lists safety assessment, pharmacodynamics, and secondary anti-tumor activity as secondary outcome areas. It also records four outcome measures. However, a complete list of outcome-level analysis methods, testing hierarchy, or adjustment for multiple comparisons is not reported in the registry record. Multiplicity matters in general when several outcomes or comparisons are examined, because the chance of a nominally notable finding can increase across repeated tests. No claim can be made about whether multiplicity was handled in the trial’s analyses.

The record describes the primary population as the intention-to-treat population, including all randomized subjects. This is an important population definition, but it does not by itself explain how missing measurements were handled. The registry does not report the number of participants with missing primary endpoint assessments, reasons for missingness, imputation methods, or sensitivity analyses. It also does not give a participant flow account that would clarify whether every randomized subject contributed endpoint data.

The registry lists zero analysis entries. It therefore does not provide detailed statistical analysis results beyond the posted outcome counts and comparison. A formal testing procedure, analysis set deviations, adjustment methods, or handling of protocol deviations are not reported in the registry record. These omissions limit assessment of how the stated population definition was implemented and how robust the findings are to incomplete data or alternative analysis choices. They do not justify assuming that a particular approach was or was not used.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: pneumonia (6.2%), demyelinating polyneuropathy (6.2%).

The serious adverse event figures list 2 affected participants among 16 at risk in the IPH2101 0.2 mg/kg group and 0 among 14 at risk in the IPH2101 2 mg/kg group. These are counts for the registry’s serious adverse event measure. The record also lists pneumonia and demyelinating polyneuropathy as serious adverse event terms, each at 6.2%. The record does not specify in the listed terms how those events were distributed by dose group, so they should not be assigned to an arm without further information.

Serious adverse event counts are not the same as counts of all adverse events, and they do not by themselves establish that an event was caused by treatment. The registry also lists 12 for the other adverse-event measure in each group, but details needed to interpret that measure are limited. Death counts are not reported in the registry record.

These figures are descriptive. The groups are small, and the record does not provide uncertainty intervals or a comparative safety analysis. The difference in observed serious-event counts should therefore not be treated as a reliable estimate of a dose-related safety difference. The registry record does not report event timing, participant-level overlap, or detailed seriousness and causality assessments.

13. What the Result Does, and Does Not, Mean

The posted primary outcome shows that no participant in either randomized group was recorded as achieving the defined objective response. The registry’s comparison reports a risk difference of 0.0. These findings describe the observed study data for IPH2101 at 0.2 mg/kg and 2 mg/kg during the stated study timeframe, using the stated confirmed-response definition.

They do not show that the true chance of response is zero in either group. The numbers of participants are limited, there are no observed primary endpoint events, and the registry does not provide usable arm-level uncertainty estimates or a described inferential method. The equal observed counts also do not establish that the two dose regimens have identical underlying response probabilities. The posted point estimate is not a substitute for a precise estimate of the dose difference.

The study had no placebo or untreated group, so the primary results do not estimate a contrast between IPH2101 and no IPH2101. The comparison is between two dose regimens. The registry record also does not report detailed results for the listed pharmacodynamic and secondary anti-tumor outcomes, and the primary response outcome does not cover all aspects of safety or disease course.

Accordingly, the result should be read as a limited descriptive finding from a randomized phase II study. It provides the observed response counts in the two groups, but the registry record does not provide enough detail to establish the precision of response-rate estimates, reconstruct a formal test, or evaluate missing-data sensitivity. It should not be extended beyond the enrolled study population, the endpoint definition, or the follow-up period described in the registry record.

14. Why This Trial Matters Statistically

This study is statistically informative as an example of the difference between an observed point estimate and the strength of evidence about an underlying effect. Both arms recorded zero primary endpoint responses, making the observed risk difference 0.0. Yet equal observed counts do not establish equal response probabilities, particularly when the event is absent and the participant groups are modest in size. A point estimate can be simple to report while its uncertainty remains difficult to evaluate.

The trial’s randomized, parallel-group design provides a framework for comparing two dose regimens. At the same time, both groups received IPH2101, so the design does not directly estimate an effect relative to an untreated or placebo group. This distinction matters when interpreting what a randomized comparison can answer: randomization concerns assignment between the study arms, while the available arms define the scope of the comparison.

The registry record also illustrates why analysis transparency matters. It names an intention-to-treat population and an endpoint definition, but the analysis entries count is zero, the interval method is not identified, and missing-data and multiplicity procedures are not reported. Without those details, readers can describe the posted counts but cannot fully assess inferential precision or analytical robustness.

Finally, planning illustrations based on an observed effect are not a substitute for the original sample-size rationale and are not observed power. Clear separation between trial design assumptions, observed results, and hypothetical planning calculations is essential to avoid overstating what a completed study demonstrates.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The primary limitation for statistical interpretation is the sparse endpoint result: no participant in either group was recorded as meeting the response definition. The registry record reports a risk difference of 0.0 and limits of 0.0 and 0.0, but does not identify the method used for those limits or provide arm-specific confidence intervals. The displayed comparison therefore does not establish the precision of the response rates or the dose contrast.

The registry lists 16 participants in the 0.2 mg/kg arm and 14 in the 2 mg/kg arm. The enrolled study is small, and the outcome has no observed events. The registry does not report the original sample-size justification or the trial’s own statistical design assumptions. Planning illustrations use stated assumptions but should not be mistaken for the original design plan or for observed power.

Further limitations arise from incomplete reporting. The record gives no analysis entries and does not describe missing primary outcome data, participant flow, sensitivity analyses, multiplicity procedures, or adjustment for other variables. The method for randomization and allocation concealment is not reported. Masking is listed as none. These details constrain assessment of potential sources of bias and the reproducibility of the analysis.

The primary comparison is between two IPH2101 dose regimens, without a placebo or untreated group. The endpoint reflects confirmed response through the study timeframe and does not encompass every clinical or safety outcome. Detailed secondary results, event timing, and deaths are not reported in the registry record. These limitations restrict interpretation to the posted data and prevent broader conclusions about comparative effects or outcomes not recorded.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma — NCT01222286.
• Registry record last updated 2026-05-14; status last verified 2026-04.
• Results first posted 2014-05-09.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

NCT01222286 is a completed randomized, open-label, parallel-group phase II study sponsored by Innate Pharma. It enrolled 30 participants with smoldering multiple myeloma and compared IPH2101 at 0.2 mg/kg with IPH2101 at 2 mg/kg. Both regimens were administered intravenously every 4 weeks over 1 hour for 6 or up to 12 cycles.

The primary endpoint was the rate of participants achieving a confirmed objective response during the study, assessed in the intention-to-treat population. The posted result is zero responses among 16 participants in the 0.2 mg/kg arm and zero among 14 in the 2 mg/kg arm. The registry comparison reports a risk difference of 0.0.

Safety, pharmacodynamics, and secondary anti-tumor activity were also listed as outcomes. The registry record does not report detailed secondary analyses, the primary comparison’s interval method, missing-data procedures, or the original sample-size justification.